Follow up approaches in thyroid cancer: a risk adapted paradigm.

[1]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[2]  R. Tuttle,et al.  Papillary thyroid cancer: monitoring and therapy. , 2007, Endocrinology and metabolism clinics of North America.

[3]  W. Wiersinga,et al.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.

[4]  Gerard M Doherty,et al.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.

[5]  Mithat Gonen,et al.  Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. , 2006, The Journal of clinical endocrinology and metabolism.

[6]  J. Shah,et al.  Low-risk differentiated thyroid cancer: The need for selective treatment , 1997, Annals of Surgical Oncology.

[7]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[8]  J. Watkinson,et al.  The British Thyroid Association guidelines for the management of thyroid cancer in adults , 2004, Nuclear medicine communications.

[9]  A. Pinchera,et al.  Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[10]  A. Oberg,et al.  Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients , 2002, World Journal of Surgery.

[11]  S. Larson,et al.  Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. , 2001, Thyroid : official journal of the American Thyroid Association.

[12]  A. Pinchera,et al.  Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. , 2001, The Journal of clinical endocrinology and metabolism.

[13]  R. Kloos,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society CLINICAL REVIEW 128 Current Approaches to Primary Therapy for Papillary , 2022 .

[14]  H. Gharib,et al.  AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. , 2001, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[15]  J. Shah,et al.  Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996 , 2000, Cancer.

[16]  D. Dean,et al.  Prognostic indicators in differentiated thyroid carcinoma. , 2000, Cancer control : journal of the Moffitt Cancer Center.

[17]  I. Hay,et al.  Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. , 1996, Surgical oncology clinics of North America.